Article

Snacking on whole almonds for six weeks increases heart rate variability during mental stress in healthy adults: a randomized controlled trial.

Vita Dikariyanto 1, Leanne Smith 1, Philip J. Chowiencyzk 2, Sarah E. Berry 1† and Wendy L Hall 1†\*

1 Department of Nutritional Sciences, School of Life Course Sciences, Faculty of Life Sciences and Medicine,

King’s College London, Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NH, UK; [vita.dikariyanto@kcl.ac.uk](mailto:vita.dikariyanto@kcl.ac.uk) (V.D.); [leanne.smith@kcl.ac.uk](mailto:leanne.smith@kcl.ac.uk) (L.S.); [sarah.e.berry@kcl.ac.uk](mailto:sarah.e.berry@kcl.ac.uk) (S.E.B); [wendy.hall@kcl.ac.uk](mailto:wendy.hall@kcl.ac.uk) (W.L.H.)

2 Department of Clinical Pharmacology, School of Cardiovascular Medicine and Sciences, Faculty of Life Sciences and Medicine, King’s College London, St Thomas’ Hospital, London SE1 7EH, UK; [phil.chowiencyzk@kcl.ac.uk](mailto:phil.chowiencyzk@kcl.ac.uk) (P. J. C.)

**\*** Correspondence: [wendy.hall@kcl.ac.uk](mailto:wendy.hall@kcl.ac.uk)

†  These authors are co-senior authors.

Received: date; Accepted: date; Published: date

**Abstract:** Cardiac autonomic regulation can be indirectly measured by heart rate variability (HRV). Low HRV, which can be induced by mental stress, is a predictor of risk of sudden cardiac death. Few studies have investigated cause-and-effect relationships between diet and HRV. Nut consumption is associated with CVD risk reduction, but the impact on HRV, particularly in response to stress, is unclear. Men and women (30-70 y) with above average risk of developing CVD were randomized onto a 6-week randomized, controlled, parallel arm trial to consume either whole almond or isocaloric control snacks (20% of daily estimated energy requirement). Control snacks contained the average nutrient profile of UK snacks. Five-minute periods of supine heart rate (HR) and HRV were measured at resting and during mental stress (Stroop color-word test) at baseline and 6 weeks. High frequency (HF) power, which reflects parasympathetic regulation of HR was increased following almonds during mental stress task relative to control (mean difference between groups 124 ms2; 95% CI 11, 237; P=0.031, n=105), but other indices were unaffected. Snacking on whole almonds instead of typical snacks may reduce risk of CVD partly by ameliorating the suppression of HRV during periods of mental stress.

**Keywords:** almonds, randomized controlled trial, heart rate variability, cardiovascular disease**,** snacking, stress

1. Introduction

Mental stress, increasingly a feature of modern fast-paced lifestyles, is recognised as contributing to the risk of developing cardiovascular disease [1,2]. Mental stressors stimulate cardiovascular responses which can be indirectly assessed via heart rate variability (HRV), a measure of fluctuation in the length of interbeat interval (IBI) modulated by the dynamic regulation of autonomic nervous system (ANS). The ANS consists of two branches that control variations in heart rate (HR), the sympathetic nervous system (SNS) which is activated by conditions of stress and increases HR, and the parasympathetic nervous system (PNS), specifically the vagus nerve, which counteracts the SNS and is dominant under conditions of rest, decreasing HR. Mental stress also attenuates baroreflex sensitivity [3] and increases endothelial dysfunction [4], which may be followed by slower recovery of HRV leading to the development of CVD risk [5,6]. Evidence from neuroimaging studies shows that HRV is associated with parts of the brain that regulate emotional responses [7], and greater cardiovascular reactivity in response to mental stress and slower recovery from stress are longitudinally linked to impaired cardiovascular risk status, including higher BP, hypertension and greater carotid intima-media thickness (subclinical atherosclerosis) [8].

HRV can be reported using the analysis of time- and frequency-domain parameters [9], as well as non-linear parameters which are able to assess complexity of patterns and randomness in the HRV signal. Low HRV indicates a dominance of sympathetic activity and suppressed parasympathetic control; prolonged low HRV indicates impaired regulation of HR in response to dynamic demands and is associated with increased risk of cardiovascular morbidity and mortality in both of general healthy population [10,11] and patients with coronary heart disease (CHD) [12-15]. Conversely, high HRV suggests resilience of the cardiac ANS in adapting to stress and is inversely associated with cardiovascular disease (CVD) [16].

Lifestyle factors, such as diet and levels of physical activity, may influence HRV [17]. Scientific understanding of the impact and mechanism of dietary modifications on HRV is still very limited [17], and mainly relates to the effects of omega-3 supplementation [18,19]. During times of stress, people are more inclined to seek reward in the shape of snack-foods with a less favourable nutrient profile, for example higher in saturated fats, refined starch, free sugars, and sodium [20,21]. Substituting typical snacks with healthier snacks may ameliorate the reduction in HRV following a stress stimulus by both these pathways. Improvements in diet quality may enhance HRV both by improving neurological function and by directly influencing the responsivity of the target organ (e.g. the heart) to parasympathetic efferent input. Diet may also indirectly enhance HRV through improving mental health and reducing psychological stress thereby reducing excess sympathetic activity [17].

In this study almonds are utilized as a model healthy snack, since they have previously been shown to have cardioprotective effects using intermediary risk factors. Almonds, the most consumed tree nut globally [22], mostly as a snack food, are rich in unsaturated fats, dietary fiber, potassium, magnesium and vitamin E, and low in saturated fatty acids, sugar and sodium [23]. Almond consumption can improve intermediary cardiovascular risk factors [24-26], such as low-density lipoprotein (LDL), apolipoprotein B (apo-B), blood pressure and adiposity [27]. Using a randomised, controlled, parallel 6-wk arm study design [28], we aimed to investigate the impact of replacing usual snacks with whole almonds on the HRV response to stress in a healthy, free-living adult population sample who were at above average risk of cardiovascular disease. It was hypothesised that snacking on almonds, relative to control snacks, would result in higher HRV during a laboratory mental stress test.

2. Materials and Methods

*2.1. Study subjects*

The ATTIS (Almond Trial Targeting dietary Intervention with Snacks) study was specifically designed to include male and female adults aged 30-70 y with moderate risk of developing CVD that were self-reported regular snack consumers (consumed 2 or more snacks per day) around London. Identification of the risk of developing CVD was conducted following the Framingham risk score system, based on total plasma cholesterol (TC), high-density lipoprotein (HDL) cholesterol, blood pressure, and BMI/waist circumference; moderate risk was defined to have score 2 or more [29].

Exclusion criteria included self-reported pre-diabetic or diabetic condition; history of heart attack (myocardial infarction) or stroke, cancer (excluding basal cell carcinoma) in the last five years, epilepsy or regular fainting, cholestatic liver disease, pancreatitis, alcohol or drug abuse; diagnosis of cardiovascular problems, angina, thrombosis, pacemaker, gastrointestinal disorders, renal or bowel disease, or; use of a drug likely to alter gastrointestinal motility or nutrient absorption; presence of metal inside the body; allergy or intolerance to nuts; currently pregnant, planning pregnancy, breastfeeding or having given birth in the preceding 12-months; unwillingness to follow the protocol and/or give informed consent; weight change of >3 kg in preceding 2-months; body mass index (BMI) of <18 kg/m2 or >40 kg/m2; current smokers or individuals who quit smoking within the last 6-months; participation in other research trials involving dietary or drug intervention and/or blood collection in the past 3-months; unable or unwilling to comply with study protocol.

Participants were recruited from the general population in the London area. Eligible potential participants were invited to a screening visit at King’s College London (KCL). Anthropometry (body height and weight, waist circumference (WC), body fat composition by bioelectrical impedance) and clinic blood pressure (cBP) were measured, and fasted blood samples were collected for analysis of blood glucose, full lipids, liver function and full blood count.

*2.2. Study design*

The ATTIS study [28] was approved by the UK National Research Ethics Service (REC 16/LO/1910, approved 24 January 2017), registered with ClinicalTrials.gov (NCT02907684), and run in accordance with the Declaration of Helsinki 1975, revised in 2013, and the principles of Good Clinical Practice. Data collection was carried out between June 2017 and May 2019. All subjects gave their informed consent for inclusion before they participated in the study. The study was primarily designed to investigate the effects of almond snack consumption on endothelial function and liver fat, with HRV as a secondary outcome.

The trial used a randomized, controlled, parallel design in a free-living cohort. Participants were randomly assigned to one of two intervention arms, almonds or control. The research coordinator conducted treatment allocation using minimization software (MinimPy 0.3, Copyright (c) 2011 Mahmoud Saghaei, <http://minimpy.sourceforge.net/>), with age, sex, ethnicity, cardiometabolic score and willingness to undergo MRI/MRS scan as minimization variables (base probability 0.7, 1:1 allocation ratio). A 2-wk run-in period consuming control snacks preceded randomization to ensure study subjects were able to tolerate the study protocol prior to starting the intervention period and to collect 4-day food diary and physical activity data. Following run-in, participants attended baseline visits at the Clinical Research Facility, St Thomas’ Hospital, London for measurements of HRV in the resting state and during a mental stress test, as well as providing a fasted blood sample, having anthropometric measurements, and other procedures to assess changes in cardiometabolic risk factors. At 2 and 4 weeks of intervention, participants attended the Metabolic Research Unit at King’s College London for measurements of body composition and they also completed 24-h dietary recalls to monitor compliance. Following 6 weeks of dietary intervention, participants attended the endpoint visit at the Clinical Research Facility, St Thomas’ Hospital and underwent the same measurements and procedures as at the baseline visit. A further 4-day food diary was completed. Before baseline and endpoint clinic visits, subjects were requested to avoid alcohol and strenuous activity for 24 h, and to consume low-fat meals and no alcohol in the evening before. Due to the nature of the intervention, participants and research staff administering interventions and conducting physiological and anthropometric measurements on study days were not blinded, but blood biomarker analysis and statistical analysis were conducted by analysts blinded to treatment allocation.

### *2.3. Intervention*

Snacks usually contribute to 20-25% of energy intake [30-32]. Thus, the dietary intervention included a 2-week run-in period, wherein participants consumed control snacks equaling 20% of estimated energy requirements (EER), followed by random allocation to either control or almond snacks at 20% of EER for 6 weeks. EER was calculated using Henry equations and physical activity level (PAL) estimated from 4-d activity diaries [33]. Control snacks were sweet and savory mini-muffins, baked at KCL, were formulated and developed to be representative of the average macronutrient intakes from snacks (excluding fruit) in the UK National Diet and Nutrition Survey population [20], as detailed elsewhere [28]. Almond snacks were dry-roasted whole non-salted almonds of the nonpareil variety, supplied by the Almond Board of California (US grade extra no. 1). Participants were provided with snack information sheets and dietary advice from the research dietitian including instructions to only consumed study snacks in between meals, maintain their habitual mealtime, eating habits and fruit consumption as well as avoid the consumption of additional nuts or nut products. To verify participants’ compliance with the dietary advice, telephone 24 h recalls and four-day estimated portion size food records were applied and conducted, as outlined in **Figure 1**.

Participants were provided with 20% EER from the muffins or almonds which for a 2000 kcal EER, equated to five control muffins daily (400 kcal in (80kcal/muffin)), or 63g/d almonds (100g almonds contains 634 kcal). Comparison of nutritional composition between almonds and control muffins is detailed in **Supplementary Table S1**. The ratio of sweet: savory muffins consumed was 70:30, with a mean of 20% of energy from free sugars in total muffins.

### *2.4. Anthropometry, blood pressure measurements, and blood sampling*

WC was measured using a measuring tape and body weight using electronic scales (Tanita BC-418MA, Tanita Ltd., Middlesex, UK). OMRON M2 Basic Intellisense monitors (OMRON Healthcare UK Ltd., Milton Keynes, UK) were used to measure seated blood pressure according to British Hypertension Society guidelines [34]. At screening, fasting blood was collected for analysis of glucose, lipids, liver function and full blood count. For baseline and endpoint visits, blood samples were taken for analysis of plasma lipids, such as total, HDL-, and LDL-cholesterol and TAG and calculated TC:HDL-C ratio, as reported previously [28]

### *2.5. HRV measurement*

HRV assessments encompass acute fluctuations in IBIs (beat-to-beat HRV, parasympathetically regulated), as well as longer-phase oscillations (also reflecting other rhythms related to thermoregulation, hormonal fluctuation and circadian patterns). To measure real-time HRV in the supine position during mental stress, a small, light-weight, chest-worn wireless 2-lead ambulatory heart rate/ECG monitor (eMotion Faros 180, Mega Electronics Ltd., Kuopio, Finland) was fitted. Mental stress was induced by requiring the participant to complete the Stroop test; a test with coloured words that has been used previously for this purpose during cardiovascular measurements [35,36]. The 5-min Stroop test was conducted 15 min after a 5-min resting HRV recording.

Cardiscope™ Analytics software (HASIBA Medical GmbH, Graz, Austria) was used to analyze the ECG data. Linear time-domain HRV parameters included the mean of the standard deviations of the normal-to-normal (NN) intervals (SDNN; indicating overall HRV) and root mean square of successive differences of NN intervals (RMSSD; indicating beat-to-beat, respiration-driven variability, and representing parasympathetic regulation) and linear frequency-domain HRV parameters included high-frequency (HF) power (reflects parasympathetic respiratory modulation) and LF/HF (previously assumed to reflect relative sympathetic to parasympathetic activity, but due to conflicting evidence for the role of the LF component in signifying sympathetic activity this has been challenged) [9,37]. HF is expressed both as absolute unit (ms2) and normalised unit (nu), the latter being an adjustment for changes in total spectral power (except VLF). The short duration of stress test in our study precluded the inclusion of VLF power (0.003-0.04 Hz), a parameter of longer-phase oscillations in autonomic regulation and the renin-angiotensin system [9].The non-linear parameter, the Poincaré ratio (SD1/SD2; the ratio of the SD of beat-to-beat IBI variability (SD1) against the SD of long-term IBI variability (SD2), indicating normality of sinoatrial firing patterns), is also measured as a non-linear measure analysis parameter [9].

### *2.6. Statistical analysis*

The sample size required per treatment arm was 50 subjects with 90% power and a two-tailed alpha set at 0.05 to detect significant between-treatment differences in flow-mediated dilation (FMD) of 1.25% unit difference (SD 1.9) [38], a primary outcome for the study. Allowing for potential drop-outs the researchers enrolled 109 subjects to commence the run-in phase. HRV measures were secondary outcomes of the ATTIS study. Due to poor quality food diaries, a per protocol analysis was performed on nutrient intake data; other data were missing due to attrition, human error or technical failure. IBM SPSS 25 was used for statistical analysis. Normality of data was assessed visually using histogram and Q-Q plot of residuals. Baseline data are shown as mean value and standard deviation (SD), unless not normally distributed and then shown as median (IQR). Treatment effects are presented as the adjusted mean differences between groups at endpoint, with 95% CI. Chi-square test was conducted to investigate whether there were differences in sex and ethnicity between control and almond group at baseline. To examine whether there were differences in other baseline characteristics and also in baseline data between the two treatment groups, independent t-test was used for normally distributed data and Mann-Whitney-U test was used for non-normally distributed data. To investigate the significance of treatment effects between the two groups, analysis of covariance (ANCOVA) was used, adjusting for baseline value and baseline BMI. A two-sided p-value of <0.05 was considered to show statistical significance.

3. Results

3.1. Participant characteristics

There were 109 participants recruited, 107 randomized and 105 completed the study. Drop-outs were due to non-compliance, time commitment issues and gastrointestinal intolerance of almonds. Table 1 shows characteristics at screening of participants who were randomized to treatment. Of 107 participants randomized, 75 were females and 32 were males, and the average age was 56 y. The CONSORT diagram in **Supplementary Figure S1** shows the full stream of participant enrolment, allocation to treatment and disposition.

**Table 1.** Subject characteristics at screening for those randomized to treatment (mean ± SD)

|  |  |  |
| --- | --- | --- |
|  | Control, n=51 | Almond, n=56 |
| Age, y | 56.0 ± 10.7 | 56.3 ± 10.3 |
| Sex, M/F, *n* | 15/36 | 17/39 |
| Ethnicity (Black/South Asian, Southeast Asian and Middle Eastern/Far East/White/Other), *n* | 2/6/2/34/7 | 9/7/3/34/3 |
| Cardiometabolic score | 4.2 ± 2.1 | 4.5 ± 2.0 |
| BMI, kg/m2 | 26.7 ± 4.5 | 27.3 ± 4.4 |
| WC, cm | 93.3 ± 12.5 | 93.6 ± 12.5 |
| % body fat | 32.7 ± 8.5 | 34.4 ± 8.4 |
| cSBP, mmHg | 124.4 ± 15.1 | 126.2 ± 17.6 |
| cDBP, mmHg | 80.6 ± 7.7 | 83.8 ± 10.8 |
| Glucose, mmol/L | 5.1 ± 0.6 | 5.1 ± 0.5 |
| TC, mmol/L | 5.6 ± 1.2 | 5.6 ± 1.0 |
| TAG, mmol/L | 1.2 ± 0.5 | 1.2 ± 0.6 |
| LDL, mmol/L | 3.5 ± 1.0 | 3.4 ± 0.9 |
| HDL, mmol/L | 1.6 ± 0.5 | 1.6 ± 0.5 |
| TC:HDL | 3.6 ± 0.9 | 3.7 ± 1.1 |

Ethnicity was determined by self-reporting.

**Table 2.** Nutrient intakes estimated from 4-d food diaries at baseline (prior to run-in) and the final week of the dietary intervention

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | Control, nmax=402 | | Almond, nmax=402 | | Mean comparison between groups | *P* value |
| Baseline | Change | Baseline | Change |
| Energy intake1, kcal/d | 2088.9 ± 538.5 | -5.8 (-124.7, 113.2) | 1769.4 ± 475.0 | -85.3 (-204.3, 33.7) | -79.5 (-251.8, 92.8) | 0.361 |
| Protein, %E | 15.4 ± 3.8 | 0.5 (-0.5, 1.5) | 15.9 ± 3.6 | 1.0 (0.0, 2.0) | 0.5 (-0.9, 1.9) | 0.466 |
| Carbohydrate, %E | 43.3 ± 7.1 | 1.7 (-0.1, 3.5) | 41.8 ± 6.6 | -7.6 (-9.4, -5.8) | -9.3 (-11.9, -6.8)\* | <0.001 |
| Starch, %E | 23.9 ± 5.1 | 2.5 (0.9, 4.1) | 23.5 ± 5.3 | -4.5 (-6.1, -2.9) | -7.0 (-9.3, -4.8)\* | <0.001 |
| Free sugars, %E | 5.9 ± 3.8 | 0.4 (-0.5, 1.2) | 5.5 ± 2.8 | -2.6 (-3.5, -1.8) | -3.0 (-4.2, -1.8)\* | <0.001 |
| Dietary fibre1, g/d | 23.8 ± 6.2 | -1.9 (-4.5, 0.6) | 20.7 ± 7.7 | 5.5 (3.0, 8.1) | 7.4 (3.8, 11.1)\* | <0.001 |
| Fat, %E | 36.5 ± 6.5 | -2.6 (-4.3, -0.8) | 37.1 ± 6.2 | 8.3 (6.5, 10.0) | 10.8 (8.4, 13.3)\* | <0.001 |
| SFA, %E | 12.3 ± 3.6 | -0.6 (-1.3, 0.1) | 12.5 ± 3.7 | -1.4 (-2.1, -0.6) | -0.7 (-1.8, 0.3) | 0.153 |
| MUFA, %E | 11.5 ± 3.4 | -1.1 (-2.4, 0.0) | 12.4 ± 3.7 | 8.6 (7.4, 9.8) | 9.8 (8.1, 11.5)\* | <0.001 |
| PUFA, %E | 5.9 ± 2.5 | -0.8 (-1.4, -0.1) | 5.9 ± 1.7 | 2.0 (1.4, 2.6) | 2.8 (1.9, 3.7)\* | <0.001 |
| Unsaturated:  saturated fatty acid ratio | 1.5 ± 0.5 | -0.1 (-0.3, 0.1) | 1.6 ± 0.7 | 1.1 (0.9, 1.3) | 1.3 (1.0, 1.5)\* | <0.001 |
| Sodium, mg | 2151.2 ± 766.3 | 179.7 (-15.8, 375.3) | 1926.1 ± 866.1 | -490.8 (-686.4, -295.3) | -670.6 (-948.6, -392.6)\* | <0.001 |
| Potassium1, mg | 3028.9 ± 936.2 | -352.5 (-590.4, -114.5) | 2534.7 ± 854.5 | 221.3 (-16.7, 459.3) | 573.8 (231.0, 916.6)\* | 0.001 |
| Calcium1, mg | 868.4 ± 455.8 | 24.2 (-57.6, 106.0) | 703.8 ± 242.5 | 57.3 (-24.5, 139.0) | 33.1 (-84.0, 150.2) | 0.575 |
| Magnesium1, mg | 368.7 ± 180.9 | -36.0 (-68.9, -3.0) | 278.5 ± 92.1 | 112.6 (79.7, 145.5) | 148.6 (100.9, 196.3)\* | <0.001 |
| Vitamin E, mg | 10.7 ± 3.7 | -1.9 (-3.5, -0.4) | 8.9 ± 4.0 | 13.5 (11.9, 15.0) | 15.4 (13.2, 17.6)\* | <0.001 |
| Riboflavin, mg | 1.8 ± 1.6 | -0.1 (-0.3, 0.0) | 1.5 ± 0.8 | 0.4 (0.2, 0.6) | 0.5 (0.3, 0.8) | <0.001 |
| Niacin, mg | 16.1 ± 8.9 | -1.6 (-3.3, 0.1) | 14.7 ± 9.4 | -0.4 (-2.1, 1.3) | 1.2 (-1.3, 3.6) | 0.339 |

Values of change and main comparison between groups are presented as mean (95% CI). ANCOVA was used, adjusted for baseline value and baseline BMI. \*p<0.05 indicating a significant difference. 1Baseline value was different between control and almond group. 2Data were analyzed using 40 diaries collected from each group. Missing data are due to poor quality diet diaries or failure to complete by participant.

*3.2. Nutrient intakes and blood markers*

Total energy intake of both treatment groups was not different as shown in **Table 2**. The almond group had significantly higher intakes of dietary fiber, fat, mono- and polyunsaturated fatty acids, the ratio of unsaturated to saturated fatty acids, potassium, magnesium, vitamin E and riboflavin. Intake of total carbohydrate, starch, free sugar and sodium was shown to be significantly lower in almond group.

There were no significant differences in changes in body composition (**Supplementary Table S3**), nor markers of insulin sensitivity (data reported elsewhere [28]). Plasma non-HDL and LDL were significantly lowered by 0.22 mmol/L (95% CI -0.42, -0.01) and 0.25 mmol/L (95% CI -0.45, -0.04) respectively following almonds relative to control, as previously reported [28].

3.3. Heart rate variability at rest and during mental stress

Compared to resting values, mean 5-min NN decreased during mental stress in both treatment groups (1030.3 ± 156.4 vs 921.1 ± 148.6, paired t-test P = <0.001). As shown in Table 3, in the resting state, there were no significant differences between treatment groups in the change in HRV indices following intervention. However, during mental stress, HF power was higher following almond treatment by 124 ms2 (95% CI 11, 237), relative to control. Moreover, LF/HF was lower by -1.0 (95% CI -1.9, -0.1) relative to control. No differences were found in other indices during mental stress.

**Table 3.** Heart rate variability values measured during 5-minute periods of rest and mental stress (Stroop test), following randomization to almond and control snacks.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | Control, nmax= 511 | | Almond, nmax= 541 | | Main comparison between groups at endpoint4 | *P*-value between groups at endpoint |
| Baseline2 | Endpoint | Baseline2 | Endpoint |
| *Resting* | | | | | | |
| NN, ms | 1009 ± 166 | 1006 (977, 1035) | 1050 ± 146 | 1012 (984, 1040) | 6 (-34, 47) | 0.760 |
| HR | 60.1 ± 10.7 | 60.5 (58.7, 62.3) | 58.0 ± 7.6 | 61.0 (59.3, 62.7) | 0.5 (-2.0, 3.0) | 0.704 |
| rMSSD, ms | 32.6 (24.6) | 37.7 (34.0, 41.5) | 31.9 (25.7) | 37.2 (33.5, 40.8) | -0.6 (-5.8, 4.7) | 0.831 |
| SDNN, ms | 54 ± 27 | 49 (44, 544) | 47 ± 21 | 50 (45, 55) | 1 (-6, 8) | 0.740 |
| SD1/SD2 | 0.5 ± 0.3 | 0.4 (0.4, 0.5) | 0.4 ± 0.1 | 0.4 (0.4, 0.5) | 0 (-0.1, 0) | 0.651 |
| HF, ms2 | 373 (631) | 599 (468, 730) | 322 (541) | 514 (391, 636) | -85 (-265, 95) | 0.348 |
| HFnu | 0.40 ± 0.17 | 0.41 (0.36, 0.46) | 0.41 ± 0.14 | 0.42 (0.37, 0.46) | 0.01 (-0.06, 0.07) | 0.871 |
| LF:HF | 1.5 (1.7) | 1.9 (1.5, 2.2) | 1.4 (1.3) | 1.9 (1.5, 2.2) | 0 (-0.5, 0.5) | 0.924 |
| *Mental stress (Stroop test)* | | | | | | |
| NN3, ms | 888 ± 166 | 935 (907, 963) | 950 ± 127 | 924 (899, 950) | -11 (-49, 28) | 0.310 |
| HR3 | 68 ± 10 | 65.4 (63.5, 67.3) | 64 ± 8 | 66.2 (64.5, 67.9) | 0.8 (-1.8, 3.4) | 0.543 |
| rMSSD, ms | 38.2 ± 22.4 | 31.8 (27.1, 36.5) | 33.8 ± 14.0 | 34.0 (29.8, 38.2) | 2.2 (-4.1, 8.5) | 0.494 |
| SDNN, ms | 54 (32) | 44 (41, 47) | 45 (22) | 48 (44, 51) | 4 (-1, 8) | 0.137 |
| SD1/SD2 | 0.4 (0.2) | 0.4 (0.3, 0.4) | 0.4 (0.1) | 0.4 (0.4, 0.4) | 0 (0, 0.1) | 0.420 |
| HF, ms2 | 394 (473) | 281 (197, 364) | 264 (495) | 405 (331, 480) | 124 (11, 237) | 0.031\* |
| HFnu | 0.31 ± 0.10 | 0.26 (0.22, 0.30) | 0.32 ± 0.12 | 0.32 (0.28, 0.35) | 0.06 (0, 0.11) | 0.040\* |
| LF:HF | 2.3 (1.5) | 3.6 (3.0, 4.3) | 2.0 (1.7) | 2.6 (2.0, 3.2) | -1.0 (-1.9, -0.1) | 0.023\* |

Endpoint values and main comparison between groups at endpoint are presented as mean (95% CI). 1Not all data were analysed due to technical problems. Resting NN, HR, rMSSD, SDNN and SD1/SD2: n = 40 (control) and 43 (almond). Resting HF, HFnu, and LF:HF: n = 35 (control) and 40 (almond). Mental stress (Stroop test) NN and HR: n = 35 (control) and 44 (almond). Mental stress (Stroop test) rMSSD, SDNN and SD1/SD2: n = 36 (control) and 44 (almond). Mental stress (Stroop test) HF, HFnu and LF:HF: n = 28 (control) and 35 (almond). 2Mean ± SD for baseline data that are normally distributed. Median (IQR) for other data as they are non-normally distributed.

3Baseline value was different between control and almond group; independent t-test was used for normally distributed data while Mann-Whitney-U test was used for non-normally distributed data; *P* < 0.05 indicating a significant difference.

4ANCOVA, adjusted for baseline outcome value and baseline BMI (mean difference almonds – control at endpoint). \**P<*0.05.

NN, normal-to-normal intervals; HR, heart rate; rMSSD, root mean square of successive R-R interval differences; SDNN, standard deviation of normal-to-normal (NN) intervals; HF, absolute power of the high-frequency band (0.15-0.04 Hz); HFnu, normalised HF (HFnu=HF/(HF+LF)).

4. Discussion

Mental stress can lower HRV, which is associated with increased risk of developing CVD [7,8]. Improvements in diet quality have the potential to increase HRV, but evidence for a direct causal relationship is limited. We report the novel finding that snacking on whole almonds for 6 weeks, compared with isocaloric snacks with a more typical nutrient profile (high in saturated fats, starch and free sugars and low in dietary fiber), increased HRV parameters of parasympathetic activity during acute mental stress. This could be due to lower levels of background daily stress in almond group, improvements in neurological autonomic function, or an increase in cardiac tissue responsivity to ANS neurotransmission and/or hormonal modulation. Although the underlying mechanism of effect is unclear, the results of the study suggest that a simple dietary modification resulting in increased intake of micronutrients, dietary fiber and unsaturated fatty acids and reduced intake of free sugars and sodium improved vagal tone during mental stress.

Variability in beat-to-beat intervals, assessed by HF power in the frequency domain, is associated with respiration, known as respiratory sinus arrhythmia (RSA). RSA is mediated by the parasympathetic nervous system modulated by vagal motor neurons linked with the lung inflation reflex [39-41]. Only a very limited amount of research has been done previously on the effects of tree nuts on HRV. In agreement with our findings, higher HF power was previously observed by Sauder et al. during two acute stress tests, i.e. mental arithmetic and hand cold pressor, following 4-week pistachio nut consumption at 20% of energy intake, as well as increased rMSSD and LF power [42]. In our study, there were no treatment effects observed for rMSSD and LF, possibly due to variability across studies in baseline stress levels and methodological differences such as type of mental stressor and measurements being made in the seated position in contrast to our study where measurements were made in the supine position. In the current study, the ratio of LF to HF power was shown to be decreased in almond group, which could suggest that replacing typical snacks with almonds might tip the balance of sympathetic to parasympathetic nervous system activity to a more favourable one. However, the interpretation of LF/HF ratio is controversial; the original belief that LF power is related to sympathetic modulation has been widely discounted as results of experiments inducing pharmacological sympathetic blockade and other manipulations of sympathetic activity [43]. Thus, the difference between treatments in LF/HF ratio is likely to be largely attributable to increased vagal tone rather than any reduction in sympathetic outflow [44,45].

Although weight loss is known to increase parasympathetic activity [46], there were no differences between groups in the change from baseline in body weight and adiposity, nor energy intake [28]. The established effects of almond consumption in lowering plasma low-density lipoprotein (LDL) cholesterol concentrations may have some bearing on HRV responses, as literature reports that plasma TC and LDL are inversely associated with HR and HRV [47,48]. Statin treatment was associated with improved HRV in 40 hypercholesterolemic patients with or without CAD [49] and healthy individuals with 48 h sleep deprivation [50]. Hypercholesterolemia elevates reactive oxygen species (ROS) and oxidative stress in vessel walls and induces inflammation, causing dysfunctional nitric oxide synthase (eNOS) activity, an enzyme catalyzing nitric oxide (NO) production and greater degradation of NO [51], resulting in dysregulation of vascular tone [52]. Baroreceptors sense systemic arterial pressures via stretching, and impaired vascular tone is likely to disrupt baroreceptor sensitivity resulting in reduced baroreflex control of HR, potentially attenuating HRV [53]. Therefore, reductions in LDL cholesterol concentrations following almond intervention may have indirectly contributed to enhancement of baroreceptor sensitivity and maintenance of vagal tone. This proposed cardiovascular mechanism is strengthened by our finding reported previously that NO-mediated vasodilation was increased following the almond intervention in the same study [28].

Lower dietary glycemic load as a result of displacing typical snack nutrient intakes with almonds may be an important factor in the improved HRV observed under mental stress, as previous studies have observed increased LF/HF and reductions in total power from spectral analysis following oral glucose loads [54-57]. Insulin secretion is implicated in this effect since hyperinsulinemia can reduce the functioning of sinoatrial node and alter ANS activity [54,55] Furthermore, literature also demonstrated that glucose intake and hyperinsulinemia are dose-dependently associated with the level of circulating NE, a sympathetic-induced neurotransmitter [58]. Sodium and potassium levels may also play a part. Potassium is inversely associated with aldosterone, a hormone regulating sodium reabsorption which is involved in renin-angiotensin-aldosterone system (RAAS). Lower sodium leads to reduced water retention in the kidney, smaller blood volume and lower blood pressure [59]. Blood pressure maintenance could promote baroreflex sensitivity and influence sympathetic activity [53].

Almonds are good source of magnesium and in this study the almond group had higher magnesium intakes relative to the control group. Animal experiments demonstrated that magnesium has anti-arrhythmic effects involving improvement in sinus rhythm [60], but human data are inconsistent in treatment of arrhythmia [61-63] and in associations with HRV [64-66]. Almonds are rich in vitamin E, and 4-month supplementation in a double-blind RCT improved HRV by increasing RR interval, TP and HF and reducing LF and LF:HF in T2D patients, possibly due to a reduction in oxidative stress [67]. Although it is not possible to pinpoint the components of almonds that may be responsible for the greater cardiac resilience to mental stress observed in the current study, it is possible that the relative augmentation in vagal tone during the Stroop test by almond consumption was a combined result of all or many of the mechanisms discussed.

The main strength of our study was the randomised, controlled, single-blinded study design involving control test snacks that represented typical snacks consumed in the adult population. Almond consumption did not affect either body weight, central adiposity (waist circumference) or overall adiposity (body fat percentage) and therefore fat mass loss was not a confounding factor [68-71]. Although we recruited healthy adults at risk of developing CVD, recording of self-reported mental and mood condition before the mental stress task and HRV measurements were not included and may be a limitation. The Stroop test was conducted following 10 min recovery after blood-pressure cuff inflation applied within flow-mediated dilation (FMD) measurement that could cause physical stress which might affect baroreceptor-derived autonomic outflow and therefore influence the resting measurements. Furthermore, it would be of interest to determine the response in recovery HRV after the Stroop test. Recruiting patients with obesity or type-2 diabetes, determinants of impaired sympathovagal balance, should a priority in future research to understand more the effects of whole almonds on HRV in at risk populations.

**5. Conclusions**

Snacking on whole almonds in place of typical snacks can increase HRV parameters of parasympathetic activity in response to mental stress, indicating improved cardiac autonomic function. Incorporating tree nuts as daily snacks is encouraged to be a positive lifestyle change and enhance cardiovascular health, not only by lowering cholesterol, but also potentially by increasing resilience to mental stress.

**Supplementary Materials:** The following are available online at www.mdpi.com/xxx/s1, Table S1: Nutritional composition of almonds and control snacks per 400 kcal isocaloric portions, Figure S1: CONSORT Flow Diagram, Table S2: Body composition, clinical blood pressure and circulating biomarkers of cardiometabolic risk following randomization to almond and control snacks.

**Author Contributions:** Conceptualization, W.L.H., P.J.C. and S.E.B.; methodology, W.L.H., V.D. and L.S.; investigation, V.D. and L.S.; data curation, V.D.; writing—original draft preparation, V.D.; writing—review and editing, W.L.H., S.E.B., L.S. and P.J.C.; supervision, W.L.H. and S.E.B.; funding acquisition, W.L.H. and S.E.B. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by the Almond Board of California and Indonesia Endowment Fund for Education. The almonds were provided by the Almond Board of California.

**Acknowledgments:** We thank Molly O’Callaghan-Latham for assistance in collecting data and all ATTIS study participants.

**Conflicts of Interest:** LS received salary from the Almond Board of California for her post as a research assistant on the study. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Appendix A

**Supplementary Materials**

**Supplemental Table S1. Nutritional composition of almonds and control snacks per 400 kcal isocaloric portions.** Values given as 20% of the estimated average requirement for energy (2000 kcal) for adult women.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Nutrient | Almonds | Average of sweet and savory control snacks | Control snacks | |
| Sweet | Savory |
| Energy, kcal | 400 | 400 | 400 | 400 |
| Protein, %E | 13.4 | 9.8 | 9.8 | 9.8 |
| Carbohydrate, %E | 13.2 | 54.1 | 54.3 | 53.8 |
| Starch, %E | - | 38.7 | 24.5 | 52.9 |
| Sugars, %E | 2.3 | 15.1 | 29.7 | 0.4 |
| Fibre, g | 9.3 | 2.1 | 1.3 | 2.8 |
| Fat, %E | 73.6 | 36.5 | 35.8 | 37.1 |
| SFA, g | 5.6 | 12.8 | 12.6 | 12.8 |
| MUFA, g | 47.9 | 16.0 | 15.8 | 16.0 |
| PUFA, g | 16.0 | 5.6 | 5.4 | 5.9 |
| Sodium, mg | <2.5 | 452.1 | 187.4 | 716.8 |
| Potassium, mg | 463.7 | 162.8 | 145.9 | 179.6 |
| Calcium, mg | 164.7 | 130.1 | 46.1 | 214.1 |
| Magnesium, mg | 181.7 | 19.0 | 15.4 | 22.6 |
| Vitamin E, mg | 14.3 | 1.3 | 1.1 | 1.4 |

**Supplemental Figure S1. CONSORT Flow Diagram**

Allocated to control group (n=51)

* Received allocated intervention (n=51)
* Did not receive allocated intervention (n=0)

Allocated to almond group (n=56)

* Received allocated intervention (n=56)
* Did not receive allocated intervention (n=0)

Allocation

Lost to follow-up (n=0)

Discontinued intervention (n=0)

Assessed for eligibility (n=294)

Excluded (n=187)

* Not meeting inclusion criteria (n=157)
* Declined to participate (n=10)
* Other reasons (n=20)

Assessed for eligibility after run-in (n=109)

Excluded (n=2)

* Not meeting inclusion criteria (non-compliance with the study protocols) (n=1)
* Declined to participate (time commitment issue) (n=1)

Enrolment

Randomized (n=107)

Lost to follow-up (n=0)

Discontinued intervention (gastrointestinal intolerance of almonds) (n=2)

Follow-Up

Analyzed (nmax=51)

Included during analysis:

* Nutrient intakes: n=40

(missing data are due to poor quality diet diaries or failure to complete by participants)

* *Blood pressure and heart rate variability*

(missing data are due to poor quality read-outs and technological problems)

* Clinical blood pressure: n=51
* Resting NN, HR, SDNN, rMSSD and SD1/SD2: n=40
* Resting HF, HFnu, and LF:HF: n=35
* Stroop test NN and HR: n=35
* Stroop test SDNN, rMSSD and SD1/SD2: n=36
* Stroop test HF, HFnu and LF:HF: n=28
* *Body composition*
* BMI: n=45, WC: n=49, Body fat: n=49
* *Circulating biomarkers*
* HOMA-IR and glucose: n=48
* Blood lipids: n=49

Analyzed (nmax=54)

Included during analysis:

* Nutrient intakes: n=40

(missing data are due to poor quality diet diaries or failure to complete by participants)

* *Blood pressure and heart rate variability*

(missing data are due to poor quality read-outs and technological issue)

* Clinical blood pressure: n=54
* Resting NN, HR, SDNN, rMSSD and SD1/SD2: n=43
* Resting HF, HFnu, and LF:HF: n=40
* Stroop test NN and HR: n=44
* Stroop test SDNN, rMSSD and SD1/SD2: n=40
* Stroop test HF, HFnu and LF:HF: n=35
* *Body composition*
* BMI: n=50, WC: n=51, Body fat: n=52
* *Circulating biomarkers*
* HOMA-IR and glucose: n=53
* Blood lipids: n=53

Analysis

**Supplemental Table S2.** **Body composition, clinical blood pressure and circulating biomarkers of cardiometabolic risk following randomization to almond and control snacks.**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | Control, nmax = 511 | | Almonds, nmax = 541 | | Main comparison between groups3 |
| Baseline2 | Change | Baseline2 | Change |
| BMI, kg/m2 | 27.1 ± 4.4 | -0.2 (-0.4, 0.0) | 27.2 ± 4.5 | 0.1 (-0.1, 0.3) | 0.2 (-0.1, 0.5) |
| WC, cm | 93.3 ± 11.7 | 0.1 (-0.9, 1.2) | 94.1 ± 12.2 | -0.6 (-1.6, 0.5) | -0.7 (-2.2, 0.8) |
| Body fat, % | 31.1 ± 7.7 | -0.5 (-1.1, 0.0) | 32.2 ± 7.7 | 0.3 (-0.3, 0.8) | 0.8 (-0.0, 1.6) |
| cSBP, mmHg | 127.8 ± 12.9 | -5.2 (-7.9, -2.6) | 127.3 ± 19.3 | -6.3 (-8.9, -3.7) | -1.0 (-4.7, 2.6) |
| cDBP, mmHg | 84.6 ± 7.9 | -3.2 (-5.1, -1.3) | 85.5 ± 10.6 | -3.5 (-5.3, -1.6) | 0.2 (-2.9, 2.4) |
| TC, mmol/L | 5.26 ± 1.13 | 0.03 (-0.15, 0.20) | 5.40 ± 0.93 | -0.18 (-0.35, -0.02) | -0.21 (-0.45, 0.03) |
| TAG, mmol/L | 1.17 (0.69) | -0.11 (-0.20, 0.01) | 1.07 (0.73) | -0.08 (-0.17, 0.02) | 0.03 (-0.11, 0.16) |
| Non-HDL, mmol/L | 3.92 ± 1.16 | 0.11 (-0.04, 0.26) | 4.00 ± 0.98 | -0.11 (-0.25, 0.03 | -0.22 (-0.42, -0.01)4 |
| LDL, mmol/L | 3.63 ± 1.16 | 0.15 (0.01, 0.30) | 3.74 ± 0.91 | -0.09 (-0.23, 0.05) | -0.25 (-0.45, -0.04)4 |
| HDL, mmol/L | 1.61 ± 0.45 | 0.04 (-0.04, 0.11) | 1.66 ± 0.51 | -0.04 (-0.11, -0.03) | -0.08 (-0.18, 0.03) |
| TC:HDL | 3.45 ± 0.91 | -0.04 (-0.15, 0.07) | 3.47 ± 1.01 | -0.03 (-0.14, 0.07) | 0.00 (-0.15, 0.16) |

Values of change and main comparison of the changes between groups are presented as mean (95% CI) generated from estimated marginal means from ANCOVA..

1Not all data were analysed due to technical problems and sample loss.

BMI: n = 45 (control) and 50 (almond).

WC: n = 49 (control) and 51 (almond).

Body fat: n = 49 (control) and 52 (almond).

TC, TAG, Non-HDL, LDL, HDL and TC:HDL: n = 49 (control) and 53 (almond).

2Median (IQR) for TAG data as they are non-normally distributed. Mean ± SD for other data that are normally distributed. Baseline biomarker values were not different between the two groups.

3ANCOVA, adjusted for baseline outcome value and baseline BMI (mean difference in change from baseline, almonds minus control); *P* < 0.05 indicating a significant difference.

4p<0.05 indicating a significant difference for values of mean difference between two groups.

BMI, body mass index; WC, waist circumference; cSBP, clinical systolic blood pressure; cDBP, clinical diastolic blood pressure; TC, total cholesterol; TAG, triglycerides; LDL, low-density lipoprotein cholesterol; HDL, high-density lipoprotein cholesterol

References

1. Sara, J.D.; Prasad, M.; Eleid, M.F.; Zhang, M.; Widmer, R.J.; Lerman, A. Association between work-related stress and coronary heart disease: a review of prospective studies through the job strain, effort-reward balance, and organizational justice models. *J Am Heart Assoc* **2018**, *7*, doi:10.1161/jaha.117.008073.

2. Glozier, N.; Tofler, G.H.; Colquhoun, D.M.; Bunker, S.J.; Clarke, D.M.; Hare, D.L.; Hickie, I.B.; Tatoulis, J.; Thompson, D.R.; Wilson, A., et al. Psychosocial risk factors for coronary heart disease. *Med J Aust* **2013**, *199*, 179-180, doi:10.5694/mja13.10440.

3. Falkner, B.; Onesti, G.; Angelakos, E.T.; Fernandes, M.; Langman, C. Cardiovascular response to mental stress in normal adolescents with hypertensive parents. Hemodynamics and mental stress in adolescents. *Hypertension* **1979**, *1*, 23-30, doi:10.1161/01.hyp.1.1.23.

4. Yeung, A.C.; Vekshtein, V.I.; Krantz, D.S.; Vita, J.A.; Ryan, T.J.; Ganz, P.; Selwyn, A.P. The effect of atherosclerosis on the vasomotor response of coronary arteries to mental stress. *New England Journal of Medicine* **1991**, *325*, 1551-1556, doi:10.1056/NEJM199111283252205.

5. Rutledge, T.; Linden, W.; Paul, D. Cardiovascular recovery from acute laboratory stress: reliability and concurrent validity. *Psychosom Med* **2000**, *62*, 648-654, doi:10.1097/00006842-200009000-00008.

6. Matthews, K.A.; Woodall, K.L.; Allen, M.T. Cardiovascular reactivity to stress predicts future blood pressure status. *Hypertension* **1993**, *22*, 479-485, doi:10.1161/01.hyp.22.4.479.

7. Thayer, J.F.; Ahs, F.; Fredrikson, M.; Sollers, J.J., 3rd; Wager, T.D. A meta-analysis of heart rate variability and neuroimaging studies: implications for heart rate variability as a marker of stress and health. *Neurosci Biobehav Rev* **2012**, *36*, 747-756, doi:10.1016/j.neubiorev.2011.11.009.

8. Chida, Y.; Steptoe, A. Greater cardiovascular responses to laboratory mental stress are associated with poor subsequent cardiovascular risk status: a meta-analysis of prospective evidence. *Hypertension* **2010**, *55*, 1026-1032, doi:10.1161/hypertensionaha.109.146621.

9. Shaffer, F.; Ginsberg, J.P. An overview of heart rate variability metrics and norms. *Front Public Health* **2017**, *5*, 258, doi:10.3389/fpubh.2017.00258.

10. Tsuji, H.; Larson, M.G.; Venditti, F.J., Jr.; Manders, E.S.; Evans, J.C.; Feldman, C.L.; Levy, D. Impact of reduced heart rate variability on risk for cardiac events. The Framingham Heart Study. *Circulation* **1996**, *94*, 2850-2855, doi:10.1161/01.cir.94.11.2850.

11. Dekker, J.M.; Schouten, E.G.; Klootwijk, P.; Pool, J.; Swenne, C.A.; Kromhout, D. Heart rate variability from short electrocardiographic recordings predicts mortality from all causes in middle-aged and elderly men. The Zutphen Study. *Am J Epidemiol* **1997**, *145*, 899-908, doi:10.1093/oxfordjournals.aje.a009049.

12. Kleiger, R.E.; Miller, J.P.; Bigger, J.T., Jr.; Moss, A.J. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. *Am J Cardiol* **1987**, *59*, 256-262, doi:10.1016/0002-9149(87)90795-8.

13. Bigger, J.T., Jr.; Fleiss, J.L.; Steinman, R.C.; Rolnitzky, L.M.; Kleiger, R.E.; Rottman, J.N. Frequency domain measures of heart period variability and mortality after myocardial infarction. *Circulation* **1992**, *85*, 164-171, doi:10.1161/01.cir.85.1.164.

14. La Rovere, M.T.; Bigger, J.T., Jr.; Marcus, F.I.; Mortara, A.; Schwartz, P.J. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators. *Lancet* **1998**, *351*, 478-484, doi:10.1016/s0140-6736(97)11144-8.

15. Balanescu, S.; Corlan, A.D.; Dorobantu, M.; Gherasim, L. Prognostic value of heart rate variability after acute myocardial infarction. *Med Sci Monit* **2004**, *10*, Cr307-315.

16. Hillebrand, S.; Gast, K.B.; de Mutsert, R.; Swenne, C.A.; Jukema, J.W.; Middeldorp, S.; Rosendaal, F.R.; Dekkers, O.M. Heart rate variability and first cardiovascular event in populations without known cardiovascular disease: meta-analysis and dose-response meta-regression. *Europace* **2013**, *15*, 742-749, doi:10.1093/europace/eus341.

17. Young, H.A.; Benton, D. Heart-rate variability: a biomarker to study the influence of nutrition on physiological and psychological health? *Behav Pharmacol* **2018**, *29*, 140-151, doi:10.1097/fbp.0000000000000383.

18. Xin, W.; Wei, W.; Li, X.Y. Short-term effects of fish-oil supplementation on heart rate variability in humans: a meta-analysis of randomized controlled trials. *Am J Clin Nutr* **2013**, *97*, 926-935, doi:10.3945/ajcn.112.049833.

19. Billman, G.E. The effects of omega-3 polyunsaturated fatty acids on cardiac rhythm: a critical reassessment. *Pharmacol Ther* **2013**, *140*, 53-80, doi:10.1016/j.pharmthera.2013.05.011.

20. Smith, L.; Dikariyanto, V.; Francis, L.; Rokib, M.; Hall, W.L.; Berry, S.E.E. Estimation of the average nutrient profile of UK snacks and development of a control snack intervention for utilisation in dietary intervention studies. In Proceedings of Nutrition Society Summer Conference 2017, London, United Kingdom.

21. Adam, T.C.; Epel, E.S. Stress, eating and the reward system. *Physiol Behav* **2007**, *91*, 449-458, doi:10.1016/j.physbeh.2007.04.011.

22. International Nut & Dried Fruit Council. Nuts & Dried Fruits: Statistical Yearbook 2018/2019. Availabe online: <https://www.nutfruit.org/files/tech/1553521370_INC_Statistical_Yearbook_2018.pdf> (accessed on 22 October).

23. U.S. Department of Agriculture. Agriculture Research Service. Food Data Central. Nuts, almonds. Availabe online: <https://fdc.nal.usda.gov/fdc-app.html#/food-details/170567/nutrients> (accessed on 9 September).

24. Berryman, C.E.; Preston, A.G.; Karmally, W.; Deckelbaum, R.J.; Kris-Etherton, P.M. Effects of almond consumption on the reduction of LDL-cholesterol: a discussion of potential mechanisms and future research directions. *Nutr Rev* **2011**, *69*, 171-185, doi:10.1111/j.1753-4887.2011.00383.x.

25. Li, S.C.; Liu, Y.H.; Liu, J.F.; Chang, W.H.; Chen, C.M.; Chen, C.Y. Almond consumption improved glycemic control and lipid profiles in patients with type 2 diabetes mellitus. *Metabolism* **2011**, *60*, 474-479, doi:10.1016/j.metabol.2010.04.009.

26. Kamil, A.; Chen, C.Y. Health benefits of almonds beyond cholesterol reduction. *J Agric Food Chem* **2012**, *60*, 6694-6702, doi:10.1021/jf2044795.

27. Lee-Bravatti, M.A.; Wang, J.; Avendano, E.E.; King, L.; Johnson, E.J.; Raman, G. Almond consumption and risk factors for cardiovascular disease: A systematic review and meta-analysis of randomized controlled trials. *Adv Nutr* **2019**, 10.1093/advances/nmz043, doi:10.1093/advances/nmz043.

28. Dikariyanto, V.; Smith, L.; Francis, L.; Robertson, M.; Kusaslan, E.; O’Callaghan-Latham, M.; Palanche, C.; D’Annibale, M.; Christodoulou, D.; Basty, N., et al. Snacking on whole almonds for 6 weeks improves endothelial function and lowers LDL cholesterol but does not affect liver fat and other cardiometabolic risk factors in healthy adults: the ATTIS study, a randomized controlled trial. *Am J Clin Nutr* **2020,** nqaa100, https://doi.org/10.1093/ajcn/nqaa100.

29. Wilson, P.W.; D'Agostino, R.B.; Levy, D.; Belanger, A.M.; Silbershatz, H.; Kannel, W.B. Prediction of coronary heart disease using risk factor categories. *Circulation* **1998**, *97*, 1837-1847, doi:10.1161/01.cir.97.18.1837.

30. Piernas, C.; Popkin, B.M. Snacking increased among U.S. adults between 1977 and 2006. *J Nutr* **2010**, *140*, 325-332, doi:10.3945/jn.109.112763.

31. Summerbell, C.D.; Moody, R.C.; Shanks, J.; Stock, M.J.; Geissler, C. Sources of energy from meals versus snacks in 220 people in four age groups. *Eur J Clin Nutr* **1995**, *49*, 33-41.

32. Smith, L.; Dikariyanto, V.; Francis, L.; Rokib, M.; Hall, W.L.; Berry, S.E. Estimation of the average nutrient profile of UK snacks and development of a control snack intervention for utilisation in dietary intervention studies. *Proceedings of the Nutrition Society* **2017**, *76*, E174, doi:10.1017/S0029665117003366.

33. Henry, C.J. Basal metabolic rate studies in humans: measurement and development of new equations. *Public Health Nutr* **2005**, *8*, 1133-1152, doi:10.1079/phn2005801.

34. Blood Pressure Measurement - Using Automated Blood Pressure Monitor. British and Irish Hypertension Society.

35. Boutcher, Y.N.; Boutcher, S.H. Cardiovascular response to Stroop: effect of verbal response and task difficulty. *Biol Psychol* **2006**, *73*, 235-241, doi:10.1016/j.biopsycho.2006.04.005.

36. Yaffe, K.; Vittinghoff, E.; Pletcher, M.J.; Hoang, T.D.; Launer, L.J.; Whitmer, R.; Coker, L.H.; Sidney, S. Early adult to midlife cardiovascular risk factors and cognitive function. *Circulation* **2014**, *129*, 1560-1567, doi:10.1161/CIRCULATIONAHA.113.004798.

37. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. *Circulation* **1996**, *93*, 1043-1065.

38. Katz, D.L.; Davidhi, A.; Ma, Y.; Kavak, Y.; Bifulco, L.; Njike, V.Y. Effects of walnuts on endothelial function in overweight adults with visceral obesity: a randomized, controlled, crossover trial. *J Am Coll Nutr* **2012**, *31*, 415-423, doi:10.1080/07315724.2012.10720468.

39. De Burgh Daly, M. Interactions Between Respiration and Circulation. In *Handbook of Physiology,*, Cherniack, N.S., Widdicombe, J.G., Eds. American Physiological Society: Bethesda, Md, 1986; Vol. Vol II: Control of Breathing, Part 2., pp. 529-594.

40. Malliani, A.; Pagani, M.; Lombardi, F.; Cerutti, S. Cardiovascular neural regulation explored in the frequency domain. *Circulation* **1991**, *84*, 482-492, doi:10.1161/01.cir.84.2.482.

41. Draghici, A.E.; Taylor, J.A. The physiological basis and measurement of heart rate variability in humans. *J Physiol Anthropol* **2016**, *35*, 22-22, doi:10.1186/s40101-016-0113-7.

42. Sauder, K.A.; McCrea, C.E.; Ulbrecht, J.S.; Kris-Etherton, P.M.; West, S.G. Pistachio nut consumption modifies systemic hemodynamics, increases heart rate variability, and reduces ambulatory blood pressure in well-controlled type 2 diabetes: a randomized trial. *J Am Heart Assoc* **2014**, *3*, doi:10.1161/jaha.114.000873.

43. Reyes del Paso, G.A.; Langewitz, W.; Mulder, L.J.; van Roon, A.; Duschek, S. The utility of low frequency heart rate variability as an index of sympathetic cardiac tone: a review with emphasis on a reanalysis of previous studies. *Psychophysiology* **2013**, *50*, 477-487, doi:10.1111/psyp.12027.

44. Billman, G.E. The LF/HF ratio does not accurately measure cardiac sympatho-vagal balance. *Front Physiol* **2013**, *4*, 26-26, doi:10.3389/fphys.2013.00026.

45. Moak, J.P.; Goldstein, D.S.; Eldadah, B.A.; Saleem, A.; Holmes, C.; Pechnik, S.; Sharabi, Y. Supine low-frequency power of heart rate variability reflects baroreflex function, not cardiac sympathetic innervation. *Heart Rhythm* **2007**, *4*, 1523-1529, doi:10.1016/j.hrthm.2007.07.019.

46. Costa, J.; Moreira, A.; Moreira, P.; Delgado, L.; Silva, D. Effects of weight changes in the autonomic nervous system: A systematic review and meta-analysis. *Clin Nutr* **2019**, *38*, 110-126, doi:10.1016/j.clnu.2018.01.006.

47. Kupari, M.; Virolainen, J.; Koskinen, P.; Tikkanen, M.J. Short-term heart rate variability and factors modifying the risk of coronary artery disease in a population sample. *Am J Cardiol* **1993**, *72*, 897-903, doi:10.1016/0002-9149(93)91103-o.

48. Christensen, J.H.; Toft, E.; Christensen, M.S.; Schmidt, E.B. Heart rate variability and plasma lipids in men with and without ischaemic heart disease. *Atherosclerosis* **1999**, *145*, 181-186, doi:10.1016/s0021-9150(99)00052-0.

49. Pehlivanidis, A.N.; Athyros, V.G.; Demitriadis, D.S.; Papageorgiou, A.A.; Bouloukos, V.J.; Kontopoulos, A.G. Heart rate variability after long-term treatment with atorvastatin in hypercholesterolaemic patients with or without coronary artery disease. *Atherosclerosis* **2001**, *157*, 463-469, doi:10.1016/s0021-9150(00)00746-2.

50. Chen, W.R.; Liu, H.B.; Sha, Y.; Shi, Y.; Wang, H.; Yin, D.W.; Chen, Y.D.; Shi, X.M. Effects of statin on arrhythmia and heart rate variability in healthy persons with 48‐hour sleep deprivation. *Journal of the American Heart Association* **2016**, *5*, e003833, doi:10.1161/JAHA.116.003833.

51. Luscher, T.F.; Noll, G. Endothelium dysfunction in the coronary circulation. *J Cardiovasc Pharmacol* **1994**, *24 Suppl 3*, S16-26.

52. Luscher, T.F.; Tanner, F.C. Endothelial regulation of vascular tone and growth. *Am J Hypertens* **1993**, *6*, 283s-293s, doi:10.1093/ajh/6.7.283s.

53. Lanfranchi, P.A.; Somers, V.K. Arterial baroreflex function and cardiovascular variability: interactions and implications. *Am J Physiol Regul Integr Comp Physiol* **2002**, *283*, R815-826, doi:10.1152/ajpregu.00051.2002.

54. Paolisso, G.; Manzella, D.; Ferrara, N.; Gambardella, A.; Abete, P.; Tagliamonte, M.R.; De Lucia, D.; Furgi, G.; Picone, C.; Gentile, S., et al. Glucose ingestion affects cardiac ANS in healthy subjects with different amounts of body fat. *Am J Physiol* **1997**, *273*, E471-478, doi:10.1152/ajpendo.1997.273.3.E471.

55. Paolisso, G.; Manzella, D.; Rizzo, M.R.; Barbieri, M.; Gambardella, A.; Varricchio, M. Effects of glucose ingestion on cardiac autonomic nervous system in healthy centenarians: differences with aged subjects. *Eur J Clin Invest* **2000**, *30*, 277-284, doi:10.1046/j.1365-2362.2000.00626.x.

56. Muscelli, E.; Emdin, M.; Natali, A.; Pratali, L.; Camastra, S.; Gastaldelli, A.; Baldi, S.; Carpeggiani, C.; Ferrannini, E. Autonomic and hemodynamic responses to insulin in lean and obese humans. *The Journal of Clinical Endocrinology & Metabolism* **1998**, *83*, 2084-2090, doi:10.1210/jcem.83.6.4878.

57. Kanaley, J.A.; Baynard, T.; Franklin, R.M.; Weinstock, R.S.; Goulopoulou, S.; Carhart, R., Jr.; Ploutz-Snyder, R.; Figueroa, A.; Fernhall, B. The effects of a glucose load and sympathetic challenge on autonomic function in obese women with and without type 2 diabetes mellitus. *Metabolism: clinical and experimental* **2007**, *56*, 778-785, doi:10.1016/j.metabol.2007.02.001.

58. Welle, S.; Lilavivat, U.; Campbell, R.G. Thermic effect of feeding in man: increased plasma norepinephrine levels following glucose but not protein or fat consumption. *Metabolism* **1981**, *30*, 953-958, doi:10.1016/0026-0495(81)90092-5.

59. Schweda, F. Salt feedback on the renin-angiotensin-aldosterone system. *Pflugers Arch* **2015**, *467*, 565-576, doi:10.1007/s00424-014-1668-y.

60. DiCarlo, L.A., Jr.; Morady, F.; de Buitleir, M.; Krol, R.B.; Schurig, L.; Annesley, T.M. Effects of magnesium sulfate on cardiac conduction and refractoriness in humans. *Journal of the American College of Cardiology* **1986**, *7*, 1356-1362, doi:10.1016/s0735-1097(86)80157-7.

61. Onalan, O.; Crystal, E.; Daoulah, A.; Lau, C.; Crystal, A.; Lashevsky, I. Meta-analysis of magnesium therapy for the acute management of rapid atrial fibrillation. *The American journal of cardiology* **2007**, *99*, 1726-1732, doi:10.1016/j.amjcard.2007.01.057.

62. Gu, W.J.; Wu, Z.J.; Wang, P.F.; Aung, L.H.H.; Yin, R.X. Intravenous magnesium prevents atrial fibrillation after coronary artery bypass grafting: a meta-analysis of 7 double-blind, placebo-controlled, randomized clinical trials. *Trials* **2012**, *13*, 41-41, doi:10.1186/1745-6215-13-41.

63. Ho, K.M.; Sheridan, D.J.; Paterson, T. Use of intravenous magnesium to treat acute onset atrial fibrillation: a meta-analysis. *Heart (British Cardiac Society)* **2007**, *93*, 1433-1440, doi:10.1136/hrt.2006.111492.

64. Kim, Y.H.; Jung, K.I.; Song, C.H. Effects of serum calcium and magnesium on heart rate variability in adult women. *Biol Trace Elem Res* **2012**, *150*, 116-122, doi:10.1007/s12011-012-9518-2.

65. Brilla, L.; Teichler, L.; Hahn, T.; Freeman, J.; Li, Y. Effect of magnesium on heart rate variability in healthy subjects. *The FASEB Journal* **2010**, *24*, 917.913-917.913, doi:10.1096/fasebj.24.1\_supplement.917.3.

66. Parikka, H.; Toivonen, L.; Naukkarinen, V.; Tierala, I.; Pohjola-Sintonen, S.; Heikkilä, J.; Nieminen, M.S. Decreases by magnesium of QT dispersion and ventricular arrhythmias in patients with acute myocardial infarction. *Eur Heart J* **1999**, *20*, 111-120, doi:10.1053/euhj.1998.1238.

67. Manzella, D.; Barbieri, M.; Ragno, E.; Paolisso, G. Chronic administration of pharmacologic doses of vitamin E improves the cardiac autonomic nervous system in patients with type 2 diabetes. *Am J Clin Nutr* **2001**, *73*, 1052-1057, doi:10.1093/ajcn/73.6.1052.

68. Lips, M.A.; de Groot, G.H.; De Kam, M.; Berends, F.J.; Wiezer, R.; Van Wagensveld, B.A.; Swank, D.J.; Luijten, A.; Pijl, H.; Burggraaf, J. Autonomic nervous system activity in diabetic and healthy obese female subjects and the effect of distinct weight loss strategies. *Eur J Endocrinol* **2013**, *169*, 383-390, doi:10.1530/eje-13-0506.

69. Facchini, M.; Malfatto, G.; Sala, L.; Silvestri, G.; Fontana, P.; Lafortuna, C.; Sartorio, A. Changes of autonomic cardiac profile after a 3-week integrated body weight reduction program in severely obese patients. *J Endocrinol Invest* **2003**, *26*, 138-142, doi:10.1007/bf03345142.

70. Poirier, P.; Hernandez, T.L.; Weil, K.M.; Shepard, T.J.; Eckel, R.H. Impact of diet-induced weight loss on the cardiac autonomic nervous system in severe obesity. *Obes Res* **2003**, *11*, 1040-1047, doi:10.1038/oby.2003.143.

71. Mouridsen, M.R.; Bendsen, N.T.; Astrup, A.; Haugaard, S.B.; Binici, Z.; Sajadieh, A. Modest weight loss in moderately overweight postmenopausal women improves heart rate variability. *Eur J Prev Cardiol* **2013**, *20*, 671-677, doi:10.1177/2047487312444367.

|  |  |
| --- | --- |
|  | © 2020 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |